Commentary

Video

The TRUST-II Study of Taletrectinib in ROS1+ Advanced NSCLC

Author(s):

Benjamin Besse, MD,Gregory J. Riely, MD, PhD

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Hidehito Horinouchi, MD, PhD
Ewa Kalinka, MD, PhD
Benjamin P. Levy, MD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Sandip P. Patel, MD
Alec Watson, MD
Related Content
Alexander Watson, MD, DPhil, FRCPC, of University of Colorado Denver
January 28th 2025

Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

PDAC | © Sebastian Kaulitzki – stock.adobe.com
January 24th 2025

RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Maurie Markman, MD
January 23rd 2025

Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care

Alexander Watson, MD, DPhil, FRCPC
January 23rd 2025

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC